Afrezza, a Long-Awaited Inhalable Anti-Diabetes Drug, Finally Receives U.S. FDA Approval

June 28, 2014 4:03 AM

11 0

The U.S. Food and Drug Administration has approved the use of Afrezza, an inhalable, fast-acting insulin powder that comes in single-use cartridges delivered through an inhaler named Dreamboat.

Earlier, in April, the FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 13 to 1 to recommend that Afrezza (insulin human [rDNA origin]) Inhalation Powder be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes.

Read more

To category page